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ABSTRACT:
It has been demonstrated that epidermal growth factor receptor (EGFR) can have 
kinase independent activity. EGFR kinase-independent function maintains intracellular 
glucose levels via sodium glucose transporter protein 1 (SGLT1) and supports cell 
survival.  It is plausible that this phenomenon can apply to other receptor tyrosine 
kinases.  We found that transfection of insulin-like growth factor receptor (IGF-1R) 
siRNA into HEK293 (human embryonic kidney) and MCF7 (metastatic breast cancer) 
cells results in decreased intracellular glucose levels, whereas treatment with the 
IGF-1R tyrosine kinase inhibitor OSI-906 did not affect intracellular glucose levels.  In 
addition, IGF-1R interacted with SGLT1 in a manner similar to that previously reported 
with EGFR. The combination of IGF-1R siRNA and OSI-906 resulted in decreased 
viability of HEK293 and MCF7 cell lines compared to either agent alone.  Collectively, 
these experiments suggest that IGF-1R, has kinase-independent biologic functions 
and provide a rationale for combining anti-IGF-1R antibodies or siRNA and IGF-1R 
small molecule inhibitors.
INTRODUCTION
Insulin-like growth factor-1 receptor (IGF-
1R) signaling is an important metabolic pathway in 
cancer.[1] IGF-1R inhibitors have shown promise in 
the clinic in several different malignancies, including 
Ewing’s sarcoma, non-small cell lung carcinoma, and 
adrenocortical carcinoma.[2-5] Both anti-IGF-1R 
antibodies and small molecules directed against the kinase 
activity of IGF-1R are being assessed in clinical trials.[4, 
6-13]  Anti-IGF-1R antibodies down-regulate cell-surface 
IGF-1R, thereby preventing signaling through IGF-1R. 
Small molecule kinase inhibitors, such as OSI-906, inhibit 
the phosphorylation and downstream signaling of IGF-1R.
[14]  While these molecules target two distinct points in 
the IGF-1 signaling pathway, the end result is thought to 
be the same, i.e. down-regulation of signaling through 
IGF-1R.
A recent publication demonstrated that epidermal 
growth factor receptor (EGFR) and other kinases signal 
through both kinase-dependent and kinase-independent 
pathways.[15, 16]. For instance, down-regulation of 
EGFR expression with small interfering (si) RNA resulted 
in a decrease in intracellular glucose levels, and induction 
of autophagy, as well as an increase in the sub-G1 
population in metastatic prostate cancer cells.[16-18]. 
These observations have important clinical implications as 
they suggest that mitigating EGFR signaling may require 
a combination of small molecule (kinase) inhibitors and 
antibodies (or siRNA). Indeed, synergy between an EGFR 
kinase inhibitor and an antibody has been demonstrated in 
preclinical models, and is being tested in the clinic.[19-23] 
It is plausible that this phenomenon may not be unique 
to EGFR and can apply to other transmembrane kinase 
receptors. In our study, we explored whether IGF-1R also 
demonstrated kinase-independent activity similar to that 
found with EGFR. 
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RESULTS
IGF-1R siRNA decreases total IGF-1R, p-IGF-1R, 
and p-Akt 
HEK293 and MCF7 cells, which both express high 
levels of IGF-1R, were transfected with siRNA against 
IGF-1R, and Western blotting was performed to confirm 
the effect of down-regulation of IGF-1R siRNA on p-IGF-
1R and p-Akt.[24, 25]. IGF-1R siRNA decreased the 
expression of total IGF-1R and p-IGF-1R in both cells 
lines (Figure 1a.), and phosphorylation of the downstream 
effector Akt was inhibited in HEK293 cells. In MCF7 
cells, Akt phosphorylation was not downregulated despite 
a decrease in total and p-IGF-1R levels, most likely 
because Akt activation is induced in these cells via both 
IGF-1R and the insulin receptor (IR).[24]. Transfection 
with EGFR siRNA served as a control for the specificity 
of IGF-1R siRNA. GAPDH siRNA served as a positive 
control for transfection (Figure 1a).  
OSI-906 decreases p-IGF-1R and p-Akt
OSI-906 is a dual kinase inhibitor that inhibits both 
IGF-1R and IR signaling. MCF7 cells express both IGF-
1R and IR (and also IR-A, the fetal isoform of IR).[24] 
Hence, IGF-1R siRNA was not sufficient to decrease 
p-Akt in MCF7 cells, but OSI-906 was (Figure 1b). This 
is consistent with data in the literature suggesting that 
Akt activation in MCF7 cells involves both IGF-1R and 
IR. Total IGF-1R remains constant following OSI-906 
treatment in both cell lines, while p-Akt and p-IGF-1R are 
decreased in a dose-dependent manner (Figure 1b).
IGF-1R siRNA decreases intracellular glucose 
levels
Previously, transfection of EGFR siRNA into 
metastatic prostate cancer cells resulted in decreased 
intracellular glucose levels, whereas treatment with an 
EGFR kinase inhibitor did not affect intracellular glucose.
[16]. GLUT is a facilitative glucose transporter, and 
SGLT1 is an active glucose transporter (sodium/glucose 
cotransporter [SGLT]). These proteins allow glucose 
to move into and out of a cell.[26, 27]  HEK293 and 
MCF7 cells were transfected with non-targeted, IGF-
1R, SGLT1, or GLUT siRNA, and intracellular glucose 
levels were measured (Figures 2a and 2b).  In both cell 
lines, intracellular glucose decreased significantly after 
transfection with IGF-1R siRNA. This was demonstrated 
in HEK293 at low/physiological extracellular glucose 
levels (5 mM), and was reversible at high (25 mM) 
glucose levels (Figure 2a). In MCF7 cells, transfection of 
IGF-1R siRNA decreased intracellular glucose levels at 
both physiological and high glucose levels (Figure 2b), 
but was more pronounced at low glucose levels. SGLT1 
and GLUT siRNA also decreased intracellular glucose 
concentrations in both cell lines, and like IGF-1R siRNA, 
the effect was only seen at low extracellular glucose 
concentrations in HEK293, and was less pronounced in 
MCF7 cells.  
Figure 1: The effect of IGF-1R siRNA or OSI-906 on p-IGF-1R and p-Akt. (a) IGF-1R siRNA decreases total IGF-1R and 
p-IGF-1R in HEK293 and MCF7 cells, and p-Akt in HEK293 cells. Cells were transfected with 100 nM siRNA for 48 hours, then lysed for 
Western blot analysis using appropriate antibodies. EGFR siRNA was used as a control for the specificity of IGF-1R siRNA, and GAPDH 
siRNA was used as a positive control for transfection. (b) The small molecule kinase inhibitor, OSI-906, inhibits phosphorylation of IGF-
1R and Akt in HEK293 and MCF7 cells in a dose-dependent manner. Total IGF-1R levels remain unchanged. Cells were treated for 48 
hours, then lysed for Western blotting. GAPDH was used as a loading control. Blots are representative of at least three experiments. 
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In contrast to IGF-1R siRNA, OSI-906 did not 
decrease intracellular glucose levels under any conditions 
(low 5mM, medium 17 mM, or high 25 mM extracellular 
glucose) when tested at concentrations up to 1 uM (Figure 
2c). Concentrations of 50 nM OSI-906 demonstrated 
complete (MCF7) or near complete (HEK293) inhibition 
of IGF-1R kinase activity (Figure 1b), but intracellular 
glucose levels remained unchanged. These results are 
analogous to those obtained with EGFR siRNA versus 
EGFR kinase inhibitors, and indicate that inhibition of 
the kinase domain of IGF-1R has no effect on the levels 
of intracellular glucose in either cell line, while down-
regulation of total IGF-1R decreases intracellular glucose.
[16]
IGF-1R and SGLT1 interact in HEK293 and MCF7 
cells
In the paper by Weihua et al., EGFR interacted with 
SGLT1, but not with GLUT, in PC3MM2 cells.[16]  We 
performed immuno-precipitation followed by Western blot 
analysis to determine if IGF-1R and SGLT1 also interact 
endogenously in our cell lines (Figure 3a). When HEK293 
or MCF7 cell lysates were immuno-precipitated with anti-
SGLT1 and Western blotted with anti-IGF-1R, a strong 
band appeared (Figure 3a, top, lane 2). This was also true 
when the antibodies were reversed (Figure 3a, bottom, 
lane 2).  GLUT, however, does not appear to interact 
with IGF-1R or EGFR (Figure 3a, top and middle panels, 
lane 3). Cell lysates were immuno-precipitated with anti-
EGFR and Western blotted with anti-SGLT1 as a positive 
control for interaction with SGLT1 (Figure 3a, bottom, 
lane 3).[16]. In addition to immuno-precipitation/Western 
blot, interaction of IGF-1R and SGLT-1 was implicated 
by experiments in which transfection of both cell lines 
with IGF-1R siRNA also resulted in a decrease in SGLT1 
protein expression, whereas non-targeted siRNA did not 
have this effect (Figure 3b, compare lanes 3 and 4). This 
is similar to results obtained for EGFR in that down-
regulation of total EGFR by siRNA transfection resulted 
in decreased expression of SGLT1 at the protein level.
Figure 2: siRNA against IGF-1R, SGLT, and GLUT decrease intracellular glucose levels, but OSI-906 does not. (a) 
IGF-1R, SGLT, and GLUT siRNA significantly decreased intracellular glucose levels in HEK293 cells cultured in low/physiologic (5mM) 
glucose DMEM, but not in high (25 mM) glucose DMEM. (b) IGF-1R, SGLT, and GLUT siRNA significantly decreased intracellular 
glucose levels in MCF7 cells cultured in low glucose, and to a lesser extent in high glucose. (c) Intracellular glucose levels were not 
significantly affected by OSI-906 (10-50 nM) in either cell line in low, medium (17 mM), or high (25 mM) glucose DMEM. All experiments 
were repeated at least three times and significance determined by student’s t test.
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[16]     
IGF-1R down-regulation does not result in 
autophagy in HEK293 and MCF7 cells
Since siRNA against EGFR was found to induce 
autophagic cell death in PC3MM2 cells, we asked whether 
this was unique to EGFR or if down-regulation of IGF-1R 
by siRNA could also induce autophagy.[16]. Autophagy 
typically occurs when the cell is under environmental 
stress, such as nutrient deprivation, or pathogen infection, 
and is used to degrade and recycle proteins and organelles 
as a means of survival, and may result in increased or 
decreased cell death depending on the circumstances.
[17, 18]. Autophagy induction was a possibility since 
levels of intracellular glucose were decreased by IGF-1R 
siRNA transfection in a manner similar to that observed 
for EGFR.[16]. However, IGF-1R siRNA did not induce 
autophagy in either HEK293 or MCF7 cells. Cells were 
transfected with non-targeted or IGF-1R siRNA and then 
immuno-stained for the presence of isoform II of the 
autophagic protein, microtubule-associated protein 1 light 
chain 3 (LC3II) (Figure 4a and 4b). Cells were analyzed 
by flow cytometry. LC3B isoform II typically increases 
in cells that are undergoing autophagy. Neither IGF-1R 
siRNA nor OSI-906 induced autophagy in either cell line. 
MG132, a proteasome inhibitor, was used as a positive 
inducer of autophagy to show that both cell lines can be 
induced to increase LC3II expression (Figure 4a and 4b, 
right panels) even though MCF7 lacks beclin1, a protein 
important to the autophagic process.[28, 29]. Results were 
confirmed by Western blot (Figure 4c and 4d). Therefore, 
unlike EGFR, IGF-1R down-regulation did not result in 
autophagy in these two cell lines. Interestingly, OSI-906 
actually decreased the level of LC3II by Western blotting 
in both cell lines. This result was seen consistently in at 
least four experiments, indicating that OSI-906 may in fact 
inhibit autophagy in these cells. Cell cycle analysis was 
also performed to determine if IGF-1R siRNA increased 
the sub-G1 population (dead/apoptotic cells) as was 
found for EGFR. Results showed that IGF-1R siRNA 
did not increase the sub-G1 population in either cell line 
(Supplementary Figure 1).   
IGF-1R siRNA decreases the viability of HEK293 
and MCF7 cells alone and in combination with 
OSI-906
We next determined whether IGF-1R siRNA and 
OSI-906 affected the viability of the cells either alone 
or in combination. Cells treated with 0.1% DMSO were 
assigned 100% viability and were used as a negative 
(vehicle) control. Cells treated with media alone were 
virtually identical to DMSO only treated cultures. Prior 
to assessing the effect on viability, the IC50 of OSI-906 
on both cell lines was determined (approximately 3 uM 
Figure 3: IGF-1R and SGLT1 interact in HEK293 and MCF7 cells, and IGF-1R siRNA transfection results in down-
regulation of SGLT1. (a) HEK293 and MCF7 cells were lysed with RIPA buffer, and 500-1000 ug of protein was immuno-precipitated 
with IgG isotypic control, anti-SGLT1, anti-GLUT, or anti-IGF-1R plus protein A/G beads. Immuno-precipitated extracts were run on an 
8% SDS-PAGE gel, immuno-blotted, and probed with anti-IGF-1R, anti-EGFR, or anti-SGLT1. Experiment shown is representative of at 
least three experiments.  Arrows indicate the interaction. (b) HEK293 and MCF7 cells were treated with vehicle (DMSO), 1 uM OSI-906, 
or transfected with non-targeted siRNA or IGF-1R siRNA for 48 hours. Inhibition of IGF-1R with siRNA also decreases protein expression 
of SGLT1 (lane 4), whereas OSI-906 has no effect on the expression of SGLT1. GAPDH served as a loading control.
Oncotarget 2013; 4: 463-473467www.impactjournals.com/oncotarget
for HEK293 at 96 hours and 500-750 nM for MCF7 at 
96 hours and 1 uM for MCF7 at 72 hours). Hence all 
viability and apoptosis experiments were carried out at 1 
uM OSI-906 at 72 or 96 hours. A cell viability assay was 
used to measure the number of viable cells present based 
on quantification of ATP, which signals the presence of 
metabolically active cells. The amount of ATP is directly 
proportional to the number of cells present in culture 
(see Materials and Methods). Cells were either treated 
with DMSO as a control (100% viability) or DMSO 
plus non-targeted siRNA, DMSO plus IGF-1R siRNA, 
OSI-906 alone, OSI-906 plus non-targeted siRNA, or 
OSI-906 plus IGF-1R siRNA. Treatment with 1 uM 
OSI-906 significantly decreased the viability of HEK293 
and MCF7 cells by approximately 26% (p<0.05) and 
50% (p<0.001), respectively, at 72 hours and by 30% 
(p<0.05) and 52% (p<0.001), respectively, at 96 hours 
(Figure 5, compare bars A and B). Hence, OSI-906 was 
more effective at decreasing the viability of MCF7 cells 
than the viability of HEK293 cells at 1 uM. These data 
correlate with the previously calculated IC50 for each 
cell line.  IGF-1R siRNA alone decreased the viability 
of HEK293 and MCF7 cells by 28% (p<0.05) and 10% 
(p<0.05), respectively, at 72 hours and 40% (p<0.05) and 
15% (p<0.05) at 96 hours (Figure 5, compare bars A and 
E).  Hence, down-regulation of total IGF-1R by siRNA 
transfection resulted in a statistically significant decrease 
in the viability of HEK293 cells and MCF7 cells at both 
time points. Cells were also transfected with non-targeted 
siRNA as a negative control. There was a non-specific 
decrease in the viability of both cell lines following 
transfection of non-targeted siRNA, but this was not 
statistically significant (Figure 5, compare bars A and C). 
The inhibitory effect of OSI-906 alone compared 
with IGF-1R siRNA alone varied with the cell line and the 
amount of time of culture. In HEK293 cells, OSI-906 and 
Figure 4: Neither IGF-1R siRNA nor OSI-906 induces the autophagic protein LC3II in HEK293 or MCF7 cells. 
HEK293 and MCF7 cells were transfected with non-targeted or IGF-1R siRNA for 48 hours (top panels, a. and b.) or treated with 1 uM 
OSI-906 for 48 hours (lower panels, a. and b.). Cells were washed in PBS and immuno-stained with primary anti-LC3B antibody, then 
stained with FITC-conjugated secondary antibody and subjected to FACS analysis. An IgG antibody was used as an isotypic control (light 
blue); baseline anti-LC3B staining (light green); non-targeted siRNA (dark blue); IGF-1R siRNA (red); DMSO (orange); OSI-906 (light 
purple). Cells were treated with 10 uM MG132 overnight as a positive control for autophagy induction (a. and b., bottom panels). LC3B 
isoforms I and II were also analyzed by Western blotting following transfection of HEK293 (c) and MCF7 (d) with siRNA or treatment with 
1 uM OSI-906 for 48 hrs. GAPDH expression served as a loading control.  NT = non-targeted siRNA.        
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IGF-1R siRNA did not differ in their ability to decrease 
viability at 72 hours, but IGF-1R siRNA was more 
effective than OSI-906 if cultured for 96 hours (Figure 
5a and 5b, compare bars B and E). In MCF7 cells, OSI-
906 was much more effective (p<0.001, Figure 5c and 5d, 
compare A and B) than IGF-1R siRNA (p<0.05, Figure 
5c and 5d, compare A and E) at decreasing viability at 72 
and 96 hours (compare bars B and E), with an enhanced 
decrease at 96 hours (Figure 5c and 5d)
If IGF-1R has both kinase-dependent and kinase-
independent effects, and if these effects are pertinent to 
cell viability, then the combination of IGF-1R siRNA 
plus OSI-906 would be expected to decrease the viability 
of both cell lines more than either agent alone. Figure 5 
shows the effect on the viability of HEK293 and MCF7 
cells treated with the combination of OSI-906 plus IGF-1R 
siRNA. Comparison of OSI-906 alone to treatment with 
OSI-906 plus IGF-1R siRNA (Figure 5, bar B compared 
to bar F) shows a significant enhancement of the effects of 
OSI-906 in both cell lines after transfection with IGF-1R 
siRNA at 72 hours and even more so at 96 hours (HEK293 
p<0.05 at 72 hours, p<0.001 at 96 hours; MCF7 p<0.05 at 
72 hours, p<0.001 at 96 hours). Alternatively, comparison 
of DMSO plus IGF-1R siRNA (essentially IGF-1R 
siRNA alone) to OSI-906 plus IGF-1R siRNA (Figure 5, 
compare bar E to bar F) also shows a significant decrease 
in viability of both cell lines at 72 hours (HEK293 p<0.05, 
MCF7 p<0.001) and 96 hours (HEK293 p<0.05, MCF7 
p<0.001).  Comparing OSI-906 plus non-targeted siRNA 
to OSI-906 plus IGF-1R siRNA (Figure 5 compare bar D 
and F) shows that IGF-1R siRNA is significantly better 
than non-targeted siRNA when combined with OSI-906 in 
HEK293 cells at 72 hours (p<0.05) and MCF7 at 96 hours 
(p<0.001), and shows a trend toward significance in MCF7 
cells at 72 hours (p=0.07). A significant difference between 
the two siRNAs was not seen in HEK293 cells at 96 hours, 
Figure 5: Viability assay results for HEK293 (low glucose) and MCF7 (high glucose) cells transfected with non-targeted 
or IGF-1R siRNA alone, treated with OSI-906 alone, or various combinations as indicated. Cells were transfected with 
either non-targeted or IGF-1R siRNA (100 nM) for 24 hours, then treated with OSI-906 (1 uM) for an additional 48 or 72 hours, giving final 
incubation times of 72 or 96 hours. (a) HEK293 - 72 hours; (b) HEK293 - 96 hours; (c) MCF7 - 72 hours; (d) MCF7 - 96 hours. Capital 
letters were added to the bar graphs for ease of comparison. A= DMSO, B= 1 uM OSI-906 alone, C= DMSO + non-targeted siRNA, D= 
OSI-906 + NT siRNA, E= DMSO + IGF-1R siRNA, F= OSI-906 + IGF-1R siRNA.  Statistical differences were determined by Student’s t 
test. P values <0.05 were considered significant.  
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perhaps because the S.E.M. was larger for this time point. 
Therefore, these results suggest that the combination of 
the kinase inhibitor OSI-906 and siRNA against IGF-1R 
has significantly greater suppressive effects on HEK293 
and MCF7 viability than either agent alone, though these 
effects are more pronounced at certain time points. 
OSI-906 and IGF-1R siRNA do not induce 
apoptosis or increase the sub-G1 population in 
HEK293 or MCF7 cells
EGFR siRNA increased the subG1 population in 
transfected metastatic prostate cancer cells [14]. Hence, 
we treated our cell lines with OSI-906 alone, IGF-1R 
siRNA alone, or the combination and performed cell 
cycle analysis. As stated above, there was no significant 
increase in the subG1 population in either cell line after 
treatment with OSI-906 or IGF-1R siRNA (Supplementary 
Figure 1). FITC-Annexin V staining was also performed 
to determine if our cell lines were undergoing apoptosis 
after treatment with OSI-906 alone or in combination 
with IGF-1R siRNA.  Baseline levels of apoptosis were 
slightly higher in MCF7 cells (22%). Treatment of MCF7 
with OSI-906 induced only a slight increase in apoptosis 
(4%) over baseline, and the combination of OSI-906 plus 
IGF-1R siRNA resulted in a 7% increase in apoptosis 
compared to OSI-906 alone (not significant by Student’s t 
test, Supplementary Figure 2). Baseline levels of apoptosis 
were lower in HEK293 cells (10%) and increased to 
approximately 18% after treatment with OSI-906 alone 
and increased to only 20% with the combination (not 
statistically significant by Student’s t test, Supplementary 
Figure 3).  Neither OSI-906, IGF-1R siRNA, nor the 
combination significantly induced apoptosis in MCF7 
and HEK293 cells. Together, these data indicate that the 
combination of OSI-906 and IGF-1R siRNA inhibits 
proliferative pathways, but does not induce apoptotic cell 
death in the cell lines studied.  
DISCUSSION
Receptor kinases can signal through more than 
one pathway. For example, CRAF was found to have 
an MEK-independent role, which is critical for mitosis 
and tumor progression.[15]. In addition, Weihua et al. 
[16] demonstrated that siRNA directed against EGFR 
resulted not only in the down-regulation of total EGFR, 
but also in a decrease in intracellular glucose levels, the 
induction of autophagic cell death, and an increase in 
the sub-G1 population. These results were not observed 
when EGFR kinase activity was inhibited, consistent 
with the presence of a kinase-independent EGFR signal. 
Additional preclinical data examining EGFR includes 
animal models showing that the combination of anti-
EGFR antibodies plus EGFR tyrosine kinase inhibitors, 
such as erlotinib, results in synergistic tumor regression.
[19-21]. We therefore asked whether a kinase-independent 
signal could be observed with other clinically relevant 
growth factor receptors, such as IGF-1R. Indeed, recent 
literature suggests that IGF-1R translocates to the nucleus 
where it is thought to be involved in the transcriptional 
enhancement of specific target genes, while the kinase 
domain of IGF-1R is responsible for interaction with 
other kinases and the activation of intracellular signaling 
pathways that result in increased proliferation.[30-36]  
Our data demonstrate that siRNA directed against 
total IGF-1R decreases intracellular glucose levels in 
both HEK293 (human embryonic kidney) and MCF7 
(metastatic breast cancer) cell lines, particularly at 
physiological levels of glucose (5 mM). Higher levels 
of extracellular glucose can partially attenuate this effect 
(Figure 2a and b). OSI-906, a small molecule inhibitor 
of the IGF-1R kinase, did not alter intracellular glucose 
levels. In addition, IGF-1R was found to interact with 
the sodium glucose transporter protein SGLT1 in a 
manner similar to that seen with EGFR. Hence, IGF-1R 
(like EGFR) may play a role in maintaining intracellular 
glucose levels in tumor cells in a kinase-independent 
manner. 
In contrast to EGFR, blocking total IGF-1R 
expression by siRNA transfection did not increase the 
sub-G1 (dead) cell population, nor did it induce autophagy 
or apoptosis in either cell line following inhibition of IGF-
1R expression; however, decreased intracellular glucose 
levels are not always a prerequisite for autophagy.[37] 
Even so, the combination of OSI-906 plus IGF-1R siRNA 
resulted in a greater decrease in cell viability in both cell 
lines than with either molecule alone (Figure 5). This may 
have clinical implications in that it suggests that giving an 
IGF-1R antibody or siRNA together with OSI-906 may be 
more effective than either agent alone. Of interest, Zeng et 
al. demonstrated an increase in autophagy in breast cancer 
cell line models (MCF-7, LCC6) sequentially exposed 
to doxorubicin and IGF-1R/IR tyrosine kinase inhibitor; 
however, autophagy in these experiments could have been 
activated by doxorubicin rather than IGF-1R inhibition.
[38]   
The case for using a monoclonal antibody and a 
kinase inhibitor together is being studied in the clinic.
[22, 23]. We recently demonstrated that 11 of 34 patients 
(32.4%) achieved stable disease for at least six months 
and/or a partial/complete response with the use of the 
EGFR kinase inhibitor erlotinib combined with the 
EGFR antibody cetuximab.[39]. Others have shown that 
combining the HER2/neu kinase inhibitor lapatinib with a 
HER2/neu antibody trastuzumab prolonged progression-
free survival in patients with HER2/neu positive breast 
cancer.[40, 41]. Our current results suggest that a similar 
strategy may be exploitable with IGF-1R inhibition.
There are limitations to this study. For instance, 
OSI-906 inhibits insulin receptor kinase as well as IGF-1R 
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kinase. It is therefore possible that the more pronounced 
decrease in cell viability observed when it was combined 
with siRNA against IGF-1R could be due to the effects on 
the insulin receptor itself. Still, these results suggest that 
such a combination in the clinic may be worth examining. 
In summary, we show that IGF-1R, like EGFR, 
demonstrates a kinase-independent function. The kinase-
independent activity is related to the interaction of 
IGF-1R with the sodium glucose transporter SGLT1; 
indeed, down-regulation of IGF-1R suppresses SGLT1, 
thereby attenuating glucose levels. Unlike EGFR, 
down-regulation of IGF-1R by siRNA does not result in 
increased autophagy. However, cell viability is decreased 
and, furthermore, combining the kinase inhibitor OSI-906 
with siRNA against IGF-1R amplifies the suppression of 
viability, albeit without a significant pro-apoptotic effect. 
These observations suggest that combining an IGF-1R 
siRNA (or antibody) with OSI-906 is warranted in the 
clinical setting. Finally, experiments are underway to 
determine if other tyrosine kinase receptors also have 
kinase-independent functions.   
MATERIALS AND METHODS
Cell lines
HEK293 (human embryonic kidney) and MCF7 
(breast adenocarcinoma) cell lines were obtained from 
American Type Culture Collection (ATCC, Manassas, 
VA), and were authenticated by short tandem repeat 
analyses. Both cell lines were maintained in Eagle’s 
Minimal Essential medium (EMEM) (ATCC) plus 10% 
fetal calf serum (FCS) and maintained in a 37oC incubator 
with 5% CO2. For cultures grown in low (5mM) or high 
(25 mM) glucose, HyClone low or high glucose DMEM 
were used, respectively (LabSource, Romeoville, IL).  
Antibodies and reagents
Primary antibodies used for Western blotting 
included rabbit polyclonal or murine monoclonal 
antibody against IGF-1R, phosphorylated (p)-IGF-1R 
(Tyr 1135/1136), Light Chain 3B (LC3B), EGFR, Akt, and 
p-Akt (ser 473) (Cell Signaling, Danvers, MA), glucose 
transporter (GLUT1), SGLT1 (Abcam, Cambridge, MA 
and Millipore, Billerica, MA), and GAPDH (Santa Cruz 
Biotechnology, Santa Cruz, CA). Secondary antibodies 
for Western blotting  included anti-rabbit (Cell Signaling) 
and anti-mouse (BioRad Laboratories, Hercules, CA) 
conjugated to horse radish peroxidise (HRP). OSI-906 was 
purchased from ChemieTek (Indianapolis, IN). Glucose 
stock (225 mM) was prepared (Invitrogen, Carlsbad, CA) 
and diluted with culture media.
siRNA transfection
siRNA transfection was performed to determine the 
effect of down-regulating IGF-1R and other molecules 
on cell signaling, survival, autophagy, apoptosis, and 
intracellular glucose levels. HEK293 (2.5x105) or MCF7 
(5x105) cells were seeded per well of a 6 well plate and 
transfected with DharmaFECT 1 siRNA lipid transfection 
reagent alone (Dharmacon, Pittsburgh, PA), non-targeted 
siRNA (siGENOME non-targeting siRNA #1), IGF-1R, 
EGFR, SGLT, GLUT, or GAPDH siRNA (control) for 48 
hours.  Following transfection, cell lysates were harvested 
for Western blot analysis, prepared for an intracellular 
glucose assay, analyzed by fluorescence activated cell 
sorter (FACS) analysis, or harvested for viability assay.     
Intracellular glucose assay
Intracellular glucose levels were measured 
following transfection of cells with IGF-1R siRNA or 
treatment with OSI-906 to determine the effects of IGF-1R 
down-regulation or inhibition of IGF-1R tyrosine kinase 
activity on intracellular glucose levels. 1x104 cells per mL 
were lysed in Western blotting solubilization buffer and 
mixed with assay reagent (1.5 mM NAD, 1.0 mM ATP, 
1.0 unit/mL of hexokinase, and 1.0 unit/mL of glucose-6-
phosphate dehydrogenase) according to the manufacturer’s 
instructions (Glucose [HK] assay kit, Sigma, St. Louis, 
MO). When glucose is phosphorylated by ATP, an 
equimolar amount of NAD is reduced to NADH. The 
consequent increase in absorbance at 340 nm of the lysate 
is directly proportional to glucose concentration.  
Immuno-precipitation and Western blotting
Immuno-precipitation followed by Western blotting 
was performed to determine if there was a physical 
interaction between IGF-1R and glucose transporter 
proteins.  For Western blots, cells were washed with 
phosphate buffered saline (PBS) and lysed in 1x RIPA 
Lysis Buffer (Millipore) plus protease inhibitors. A 
modified Lowry protein assay was performed (Pierce 
Biotechnology, Rockford, IL), and equal amounts of 
protein were loaded onto 7.5-10% SDS-PAGE gels, and 
then transferred to nitrocellulose membranes by electro-
blotting.  Blots were blocked in 5.0% non-fat milk, 
incubated with primary antibody (22oC for 2 hours), 
washed, and then incubated with an appropriate secondary 
antibody conjugated to HRP and detected by enhanced 
chemiluminescence (Amersham Pharmacia Biotech, 
Piscataway, NJ).  For immuno-precipitation experiments, 
cells were lysed in RIPA buffer (Pierce Biotechnology). 
500-1000 ug per lane of lysate was pre-cleared with an 
isotypic control (Santa Cruz Biotechnology) (4oC for 2 
Oncotarget 2013; 4: 463-473471www.impactjournals.com/oncotarget
hours), then incubated with specific antibody plus protein 
A/G beads (2-4 hours at 4oC), centrifuged, washed 4X with 
RIPA buffer, resuspended in 2X sample buffer (BioRad), 
and boiled before loading onto SDS-PAGE gels.
Analysis of autophagy by LC3B staining and flow 
cytometry 
To determine if cells were undergoing autophagy, 
levels of the autophagosomal protein LC3B isoform II 
were measured by staining the cells with an anti-LC3B 
antibody, and then analyzing by flow cytometry. HEK293 
(2.5x105)  and MCF7 (5x105) cells were transfected with 
the appropriate siRNA or treated with DMSO (vehicle) or 
OSI-906 for 48 hours, washed in PBS, and fixed by adding 
2-4% formaldehyde solution for 10 minutes at 37oC. 
Cells were then permeabilized by adding ice-cold 100% 
methanol to pre-chilled cells to a final concentration of 
90% and incubated on ice for 30 minutes. 0.5-1x106 cells 
per tube were washed twice in 0.5% bovine serum albumin 
(BSA) in PBS. Cells were blocked in 0.5% BSA for 10 
minutes at room temperature (RT). Primary antibody (anti-
LC3B) was added at a 1:500 dilution and incubated for 1 
hour at RT, then washed with 0.5% BSA. FITC-conjugated 
secondary antibody (1:1,000) was added and cells were 
incubated for 30 minutes at RT, washed, and resuspended 
in 0.5 mL PBS and analyzed by fluorescence activated cell 
sorter (FACS) analysis (Becton Dickinson, Bedford, MA).
Viability assay
Viability of the cells was assessed after treating the 
cells with OSI-906, IGF-1R siRNA, or the combination. 
500 HEK293 or 1x103 MCF7 cells were plated per well 
of an opaque-walled 96-well plate. The CellTiter-Glo® 
Luminescent Cell Viability Assay (Promega, Madison, 
WI) was used to measure the number of viable cells 
present based on quantification of ATP, which signals the 
presence of metabolically active cells. The amount of ATP 
is directly proportional to the number of cells present in 
culture. The assay was performed at RT as described in 
the manufacturer’s instructions. Background luminescence 
from wells containing media alone was subtracted from 
experimental wells. 100 uL of CellTiter-Glo ® Reagent 
was added per well containing 100 uL of culture medium. 
Contents were mixed on an orbital shaker for 2 minutes 
to induce cell lysis, and the plate was incubated at RT for 
10 minutes to stabilize the luminescent signal. Plates were 
read on a BioTek Synergy 4 plate reader (Winooski, VT).
Annexin V apoptosis assay
Following transfection with IGF-1R siRNA or 
treatment with OSI-906 or the combination, apoptosis 
was measured by staining cell-surface phosphatidyl serine 
with FITC-conjugated Annexin V. 2.5x105 HEK293 and 
5x105 MCF7 cells were seeded per well of a six-well 
plate and treated for 72 hours, harvested, and stained with 
FITC-Annexin V and propidium iodide according to the 
manufacturer’s instructions (BD Pharmingen). Cells were 
analyzed using fluorescence activated cell sorter (FACS) 
analysis (Becton Dickinson).
Cell cycle analysis  
Cell cycle analysis was performed to determine if 
there was an increase in the sub-G1(dead cell) population 
following transfection with IGF-1R siRNA or treatment 
with OSI-906. Cells were fixed in 100% ethanol 
and stained with propidium iodide, according to the 
manufacturer’s instructions (BD Pharmingen), and then 
analyzed using FACS analysis. 
Statistical analysis
Student’s t-test was used to assess the association 
between continuous variables. All tests were two-sided, 
and P values less than 0.05 were considered statistically 
significant. If not otherwise indicated, error bars in all 
experiments represent standard deviation error (SE). 
All statistical analyses were carried out using SPSS 19 
computer software (SPSS Chicago, IL).
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